Antidiabetic potential of Amomum dealbatum Roxb. flower and isolation of three bioactive compounds with molecular docking and in vivo study. 2023

Nilamoni Chelleng, and Tanjila Begum, and Partha Pratim Dutta, and Pankaj Chetia, and Saikat Sen, and Biplab Kr Dey, and Narayan Chandra Talukdar, and Chandan Tamuly
Natural Product Chemistry Section, CSIR-North East Institute of Science and Technology, Naharlagun, Arunachal Pradesh, India.

Amomum dealbatum Roxb. parts have been traditionally used as remedies for joint pain, diabetes, muscular rheumatism, antiseptic, and abscesses in Arunachal Pradesh, Assam, and Tripura. Ethyl acetate sub-fraction E3 had significantly inhibited the α-glucosidase (IC50 5.385 μg/mL). The molecular docking revealed quercetin-3-O-galactoside to be the most potent α-glucosidase inhibitor (binding energy -43.214 kcal/mol). Using the QSAR model, the pIC50 values of myricetin, gallic acid, quercetin-3-O-galactoside, and acarbose were predicted to be 5.65235, 4.39858, 5.65235, and 6.03058, respectively. For the first time, quercetin-3-O-galactoside, myricetin, and gallic acid have been isolated from the flowers of A. dealbatum (ADF). E3 decreased blood glucose level to a near-normal concentration (100.60 ± 2.94 mg/dL) in comparison to diabetic control rats (575.20 ± 24.80 mg/dL). The results have strongly suggested the potential of ADF in treating diabetes. This lesser-known plant has the potential to uncover its full medicinal properties through further in-depth research.

UI MeSH Term Description Entries

Related Publications

Nilamoni Chelleng, and Tanjila Begum, and Partha Pratim Dutta, and Pankaj Chetia, and Saikat Sen, and Biplab Kr Dey, and Narayan Chandra Talukdar, and Chandan Tamuly
September 2020, Pakistan journal of pharmaceutical sciences,
Nilamoni Chelleng, and Tanjila Begum, and Partha Pratim Dutta, and Pankaj Chetia, and Saikat Sen, and Biplab Kr Dey, and Narayan Chandra Talukdar, and Chandan Tamuly
January 2019, Drug design, development and therapy,
Nilamoni Chelleng, and Tanjila Begum, and Partha Pratim Dutta, and Pankaj Chetia, and Saikat Sen, and Biplab Kr Dey, and Narayan Chandra Talukdar, and Chandan Tamuly
October 2025, Preparative biochemistry & biotechnology,
Nilamoni Chelleng, and Tanjila Begum, and Partha Pratim Dutta, and Pankaj Chetia, and Saikat Sen, and Biplab Kr Dey, and Narayan Chandra Talukdar, and Chandan Tamuly
March 2022, Journal of food biochemistry,
Nilamoni Chelleng, and Tanjila Begum, and Partha Pratim Dutta, and Pankaj Chetia, and Saikat Sen, and Biplab Kr Dey, and Narayan Chandra Talukdar, and Chandan Tamuly
January 2022, Evidence-based complementary and alternative medicine : eCAM,
Nilamoni Chelleng, and Tanjila Begum, and Partha Pratim Dutta, and Pankaj Chetia, and Saikat Sen, and Biplab Kr Dey, and Narayan Chandra Talukdar, and Chandan Tamuly
January 2022, Frontiers in pharmacology,
Nilamoni Chelleng, and Tanjila Begum, and Partha Pratim Dutta, and Pankaj Chetia, and Saikat Sen, and Biplab Kr Dey, and Narayan Chandra Talukdar, and Chandan Tamuly
December 2025, Food chemistry,
Nilamoni Chelleng, and Tanjila Begum, and Partha Pratim Dutta, and Pankaj Chetia, and Saikat Sen, and Biplab Kr Dey, and Narayan Chandra Talukdar, and Chandan Tamuly
January 2022, Bioinformation,
Nilamoni Chelleng, and Tanjila Begum, and Partha Pratim Dutta, and Pankaj Chetia, and Saikat Sen, and Biplab Kr Dey, and Narayan Chandra Talukdar, and Chandan Tamuly
January 2016, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques,
Nilamoni Chelleng, and Tanjila Begum, and Partha Pratim Dutta, and Pankaj Chetia, and Saikat Sen, and Biplab Kr Dey, and Narayan Chandra Talukdar, and Chandan Tamuly
October 2020, Scientific reports,
Copied contents to your clipboard!